INT142184

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2004
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 8.25
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (TXK) nucleus (TXK) DNA binding (TXK)
cytoplasm (TXK)
TXK (Homo sapiens)
Pain Link Frequency Relevance Heat
COX-2 inhibitor 4 99.52 Very High Very High Very High
antagonist 8 95.96 Very High Very High Very High
Nicotine 58 78.76 Quite High
amygdala 1 75.60 Quite High
Potency 3 75.00 Quite High
midbrain 1 73.92 Quite High
Pain 8 61.04 Quite High
Inflammation 23 59.12 Quite High
nud 3 59.12 Quite High
addiction 39 51.96 Quite High
Disease Link Frequency Relevance Heat
Myeloid Leukemia 55 99.86 Very High Very High Very High
Endometriosis (extended) 12 99.56 Very High Very High Very High
Breast Cancer 94 99.00 Very High Very High Very High
Cancer 335 98.24 Very High Very High Very High
Congenital Anomalies 1 97.84 Very High Very High Very High
Fibromyalgia 4 96.60 Very High Very High Very High
Hematological Disease 1 96.48 Very High Very High Very High
Disease 158 96.32 Very High Very High Very High
Malignant Neoplastic Disease 20 95.52 Very High Very High Very High
Ovarian Cancer 100 95.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Vatalanib is a multitargeted tyrosine kinase inhibitor targeting angiogenesis that inhibits PDGFRB, VEGFR1, VEGFR2, c-Kit, and c-Fms.
Regulation (multitargeted) of tyrosine kinase associated with fibromyalgia
1) Confidence 0.11 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 1.74 Pain Relevance 0.03
Insulin acted at the insulin receptor via pathways dependent on tyrosine kinase and phosphatidylinositol 3 kinase because the insulin effect was eliminated by the insulin receptor antagonist, hydroxy-2-naphthalenylmethylphosphonic acid trisacetoxymethyl ester, the tyrosine kinase inhibitor lavendustin A, and the phosphatidylinositol 3 kinase antagonist wortmannin.
Regulation (dependent) of tyrosine kinase associated with antagonist
2) Confidence 0.06 Published 2007 Journal Mol. Pharmacol. Section Abstract Doc Link 17308032 Disease Relevance 0.06 Pain Relevance 0.23
ZD 1839 (gefitinib) is an example of an orally active, selective EGFR tyrosine kinase inhibitor, which has shown extensive preclinical activity.
Regulation (selective) of tyrosine kinase
3) Confidence 0.05 Published 2008 Journal Breast Cancer Res Section Body Doc Link PMC2575526 Disease Relevance 0.78 Pain Relevance 0
Small tyrosine kinase inhibitors that target VEGFR are a further important class of anti-angiogenic drugs.
Regulation (target) of tyrosine kinase
4) Confidence 0.03 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.63 Pain Relevance 0.04
In contrast, therapies targeting the HER2 receptor and HER2 tyrosine kinase have shown great clinical efficacy in this tumor subtype with a poor natural history.
Regulation (targeting) of tyrosine kinase associated with cancer
5) Confidence 0.02 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.90 Pain Relevance 0
Changes in estimated percentage breast density, oestradiol, FSH, LH, tyrosine kinase activity, menopausal symptom score, and number of hot flushes from baseline to 12 months were expressed as absolute change (i.e. 12-month data – baseline data).
Regulation (Changes) of tyrosine kinase associated with endometriosis (extended)
6) Confidence 0.01 Published 2004 Journal Breast Cancer Res Section Body Doc Link PMC400670 Disease Relevance 0.17 Pain Relevance 0
Hence the standard care for treating CML is to target Bcr Abl tyrosine kinase by the pharmacological inhibitors Imatinib or more potent Dasatinib and Nilotinib [17].
Regulation (target) of tyrosine kinase associated with myeloid leukemia
7) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2806839 Disease Relevance 1.02 Pain Relevance 0
Ligand interactions with CDH13 activate signaling pathways including those that alter intracellular Ca2+ and tyrosine kinase, Erk 1/2 kinase, RhoA/ROCK and Rac pathways and NFkB [37-40].
Regulation (alter) of tyrosine kinase
8) Confidence 0.01 Published 2007 Journal BMC Genet Section Body Doc Link PMC1853105 Disease Relevance 0.32 Pain Relevance 0.17
KIT positivity is important as it is one of the targets of the tyrosine kinase inhibitor imatinib mesylate.
Regulation (targets) of tyrosine kinase
9) Confidence 0.01 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503651 Disease Relevance 0.94 Pain Relevance 0
The early success of imatinib in chronic phase CML led investigators to assess its effects on c-KIT receptor tyrosine kinase activity (Heinrich et al 2000).
Spec (investigators) Regulation (effects) of tyrosine kinase associated with myeloid leukemia
10) Confidence 0.01 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503651 Disease Relevance 0.72 Pain Relevance 0
In recent years, the amount of cytotoxic agents and targeted therapies used to treat HNSCC, include classic chemotherapeutic agents, chemoprevention agents such as COX-2 inhibitors, monoclonal antibodies targeting tyrosine kinase receptors, small molecule tyrosine kinase inhibitors, and antiangiogenic drugs [90].
Regulation (targeting) of small molecule tyrosine kinase associated with cox-2 inhibitor
11) Confidence 0.00 Published 2011 Journal Journal of Oncology Section Body Doc Link PMC3010684 Disease Relevance 0.98 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox